新型组织工程化心脏瓣膜材料的体外生物学性能评价

胡行健; 史嘉玮; 董念国; 邓成; 史峰

doi:10.13201/j.issn.1001-1439.2014.01.022

新型组织工程化心脏瓣膜材料的体外生物学性能评价

- 华中科技大学附属协和医院心外科(武汉, 430022)
基金项目:
国家863高技术研究发展计划资助项目 (No:2009AA03Z420)

国家自然科学基金资助项目 (No:30872540

81170214)

详细信息

通讯作者: 董念国, E-mail:dongnianguo@hotmail.com

中图分类号: R542.5

收稿日期: 2013-05-16

Biological evaluation of novel tissue engineering heart valve material in vitro

- Department of Cardiovascular Surgery, Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Corresponding author: DONG Nianguo, E-mail: dongnianguo@hotmail.com

Received Date: 16 May 2013

摘要

摘要: 目的:评价枝化状聚乙二醇 (PEG) 交联去细胞猪主动脉瓣的生物相容性。方法:依据GB/T16886.6-1997标准, 利用直接接触法和浸提液接触法 (间接接触) 检测所制备的组织工程化心脏瓣膜材料的致凝血性能、致溶血性能, 采用AlamarBlue^{^®}细胞活力检测法和Annexin V凋亡检测法评价材料的细胞毒性, 并应用形态学方法检测瓣膜表面细胞粘附增殖情况, 以新鲜天然瓣膜和去细胞瓣膜作为对照。结果:新型材料不会明显刺激血小板引起其粘附、激活 (与天然瓣膜对比, P>0.5)。材料接触对凝血功能 (INR, APTT) 无显著影响。材料直接或间接溶血率均符合生物材料国家标准。AlamarBlue^{^®}法检测显示, 与材料直接或间接接触对细胞增殖无显著影响, 间接接触不增加细胞凋亡概率 (P>0.1)。细胞接种于材料表面后增殖迅速, 形态正常, 扫描电镜示细胞连接致密, 呈单层排列覆盖材料。结论:枝化状PEG交联去细胞猪主动脉瓣的离体生物相容性达到GB/T16886.6-1997标准, 是一种有潜力的组织工程化心脏瓣膜替代材料。
- 组织工程 /
- 心脏瓣膜 /
- 生物性能 /
- 离体
Abstract: Objective:To evaluate the biocompatibility of polyethylene glycol (PEG) cross-linked decellularized porcine aortic valve leaflets which knew as "novel tissue engineering heart valve (TEHV) material".Method:According to GB/T16886.6-1997standard, the direct contact method and the extraction liquid contact (indirect contact) method were adopted to test the biological properties of the TEHV material such as hemostasis and hemolytic properties, while the AlamarBlue^{^®} cell vitality assay and Annexin V apoptosis assay were also used to evaluate the cytotoxicity of the material.Adhesion and proliferation of cells on the material surface were assessed with morphological method.Fresh porcine valves and decellularized valves were chosen as control.Result:The novel material did not activate platelet and promote platelet adhesion obviously (compared with fresh valve, P>0.5). Direct and indirect contact with the material had no significant impacts on blood coagulation (INR, APTT).Direct and indirect contact hemolysis rate of the material conformed to the state standards.AlamarBlue^{^®} assay showed that direct or indirect contact with material had no significant influences on cell proliferation.Indirect contact didn't cause apoptosis rate increase (P>0.1).After incubation, the cell proliferated rapidly with normal form on the material surface, scanning electron microscopy (SEM) proved the material surface was covered by a monolayer of cells which connected tightly.Conclusion:PEG cross-linked decellularized porcine aortic valve shows great in vitro biocompatibility conforming to GB/T16886.6-1997state standard and could be a promising novel material for TEHV or biological heart valve manufacture.
- tissue engineering /
- heart valve /
- biocompatibility /
- in vitro

HTML全文

参考文献(9)

[1]	胡盛寿, 孔灵芝.卫生部心血管病防治研究中心.中国心血管病报告:2008-2009[M].北京:中国大百科全书出版社, 2010:10-11.
[2]	FANG N T, XIE S Z, WANG S M, et al.Construction of tissue-engineered heart valves by using decellularized scaffolds and endothelial progenitor cells[J].Chin Med J (Engl), 2007, 120:696-702.
[3]	KOROSSIS S A, BOOTH C, WILCOX H E, et al.Tissue engineering of cardiac valve prosthesesⅡ:biomechanical characterization of decellularized porcine aortic heart valves[J].J Heart Valve Dis, 2002, 11:463-471.
[4]	邹明晖, 周建良, 董念国, 等.枝化状聚乙二醇交联改善猪去细胞主动脉瓣的力学性能比较[J].中华实验外科杂志, 2011, 28 (5):759-761.
[5]	邹明晖, 周建良, 董念国, 等.聚乙二醇交联去细胞瓣构建组织工程瓣膜复合支架[J].中华临床医师杂志, 2011, 5 (8):22-25.
[6]	董念国, 叶晓峰, 史嘉玮, 等.组织工程瓣膜天然支架去细胞方法的比较[J].中华实验外科杂志, 2005, 22 (3):377-378.
[7]	CHEN J S, NOAH E M, PALLUA N, et al.The use of bifunctional polyethylene glycol derivatives for coupling of proteins to and cross-linking of collagen matrices[J].J Mater Sci Mater Med, 2002, 13:1029-1035.
[8]	VERONESE F M, MERO A.The impact of PEGylation on biological therapies[J].Bio Drugs, 2008, 22:315-329.
[9]	BANERJEE S S, AHER N, PATIL R, et al.Poly (ethylene glycol)-prodrug conjugates:concept, design, and applications[J].J Drug Deliv, doi:10.1155/2012/103973.